Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial.

Subjects

Subjects :

ADENOCARCINOMA
STOMACH tumors
PATIENT safety
RESEARCH funding
ANTINEOPLASTIC agents
STATISTICAL sampling
BLIND experiment
PROGRAMMED death-ligand 1
ESOPHAGEAL tumors
TREATMENT effectiveness
RANDOMIZED controlled trials
DESCRIPTIVE statistics
MONOCLONAL antibodies
CANCER chemotherapy
METASTASIS
DRUG efficacy
COMPARATIVE studies
CONFIDENCE intervals
EPIDERMAL growth factor receptors
OVERALL survival
PHARMACODYNAMICS

Details

Language :

English

ISSN :

17561833

Volume :

385

Issue :

8431

Database :

Complementary Index

Journal :

BMJ: British Medical Journal

Publication Type :

Academic Journal

Accession number :

177767724

Full Text :

https://doi.org/10.1136/bmj-2023-078876